Alkermes to Report Third Quarter Financial Results on November 3, 2026

Alkermes (Nasdaq: ALKS) will host a conference call and webcast on November 3, 2026 to discuss third quarter financial results.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial results.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.

About Alkermes plc

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020456820/en/

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Source: Alkermes plc

Key Terms

idiopathic hypersomnia medical

A chronic sleep disorder that causes extreme daytime sleepiness and prolonged, unrefreshing sleep despite adequate night sleep, with no identifiable medical or neurological cause. Think of it like a phone battery that won’t hold charge: sufferers remain tired and less productive even after long rest. For investors, idiopathic hypersomnia matters because it creates demand for treatments, diagnostics and supportive services, influencing market opportunities and regulatory pathways in sleep medicine.

orexin 2 receptor agonists medical

Orexin 2 receptor agonists are drugs that stimulate a specific receptor in the brain involved in wakefulness; think of them as turning up a targeted “wake” switch to help people stay alert. For investors, these medicines matter because successful clinical trial results or regulatory approval can create a new treatment market for sleep disorders and affect the value, revenue prospects, and risk profile of companies developing them.